Intervention

etanercept

ClinicalTrials.gov intervention label

Clinical trials25

Recruiting0

Common conditions25

Lead sponsors shown15

Clinical trials

25 shown

Treatment Tapering in JIA With Inactive DiseaseNCT02840175 · 2017-05-18

Anti-inflammatory Therapy to Improve Outcomes After TPIATNCT02713997 · 2016-12-01

Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"NCT02878161 · 2016-01-01

Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis SubjectsNCT02378506 · 2015-04-01

Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical PracticeNCT02202837 · 2014-08-12

Effects of Treatment With Biological Agents on Vascular and Cardiac Function in PsoriasisNCT02144857 · 2014-05-30

Etanercept in Rheumatoid Arthritis and Vascular InflammationNCT02109289 · 2014-04-01

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid ArthritisNCT02092467 · 2014-03-14

Good EULAR Response In Patients With Early Rheumatoid ArthritisNCT01558089 · 2013-03-01

Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics RegistryNCT01646385 · 2012-02-01

Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)NCT01557322 · 2011-10-01

Islet After Kidney Transplant for Type 1 DiabetesNCT00784966 · 2011-08-01

Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)NCT01313208 · 2011-03-01

Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid ArthritisNCT00913458 · 2009-09-01

Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type PsoriasisNCT00800982 · 2008-10-01

A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)NCT00724672 · 2008-09-01

A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid ArthritisNCT00484237 · 2007-04-01

Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RANCT00418717 · 2007-02-01

Observational Trial With EnbrelNCT00488475 · 2006-09-01

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell TransplantNCT00309907 · 2006-04-01

Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint SynovitisNCT00678782 · 2005-04-01

Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)NCT00259610 · 2004-05-01

Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In LuxemburgNCT00195338 · 2004-05-01

A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV DiseaseNCT00205231 · 2002-05-01

Etanercept for Non-Infectious Lung Injury Following Bone Marrow TransplantationNCT00029328 · 2001-09-01

Common conditions

Rheumatoid Arthritis13 Arthritis, Rheumatoid4 Psoriasis2 Accelerated Phase Chronic Myelogenous Leukemia1 Active Rheumatoid Arthritis1 Blastic Phase Chronic Myelogenous Leukemia1 Bronchiolitis Obliterans1 Childhood Acute Lymphoblastic Leukemia in Remission1 Childhood Acute Myeloid Leukemia in Remission1 Childhood Chronic Myelogenous Leukemia1 Childhood Myelodysplastic Syndromes1 Chronic Phase Chronic Myelogenous Leukemia1 de Novo Myelodysplastic Syndromes1 Disseminated Neuroblastoma1 HIV Infections1 Juvenile Idiopathic Arthritis1 Juvenile Myelomonocytic Leukemia1 Pancreatitis, Chronic; Diabetes; Transplant1 Persistent Knee Joint Synovitis1 Pneumonia1 Previously Treated Childhood Rhabdomyosarcoma1 Previously Treated Myelodysplastic Syndromes1 Pulmonary Complications1 Recurrent Childhood Acute Lymphoblastic Leukemia1 Recurrent Childhood Acute Myeloid Leukemia1

Leading sponsors

Pfizer9 Wyeth is now a wholly owned subsidiary of Pfizer2 Amgen1 Assistance Publique - Hôpitaux de Paris1 Children's Oncology Group1 FDA Office of Orphan Products Development1 Fen Li1 Innovaderm Research Inc.1 Merck Sharp & Dohme LLC1 University of Alabama at Birmingham1 University of Athens1 University of California, San Francisco1 University of Minnesota1 University of Padova1 University of Wisconsin, Madison1

Trial status mix

COMPLETED20

UNKNOWN2

WITHDRAWN2

TERMINATED1

Phase mix

PHASE48

PHASE24

PHASE34

NA2

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.